The southern region of Belgium, Wallonia, has grown into a major European hub for biopharma research andmanufacturing. Ludovic Waha, Senior Life Sciences Busines...

Why CDMOs should consolidate their QMS landscape and how to do it well Quality management systems (QMS) that are not continuously challenged and optimised pos...

Biopharmas have been advancing in how they connect data and processes across clinical, regulatory, safety and quality. In 2026, the operational focus will shift ...

Breast cancer is the most common cancer in women worldwide. It is highly heterogeneous with distinct breastcancer subtypes, posing challenges for diagnosis and t...

Drug-induced arrhythmias remain a significant challenge in pharmaceutical development, often resulting inlate-stage failure, regulatory rejection and post-market...

The challenges of collaboration between pharmaceutical companies and contract research organisations (CROs) are widely discussed across the industry. Ask leaders...

Population growth, shrinking arable land and climate change are intensifying pressure on global food systems.Microorganism-based ingredients offer a compelling a...

Antibody–drug conjugates (ADCs) are at the forefront of targeted therapy, combining the precision of monoclonal antibodies with the efficacy of cytotoxic agents,...

Demand for end-to-end, integrated manufacturing capabilities continues to amplify in the biopharmaceuticalindustry amid lingering operational and regulatory chal...

The Shift Towards an Integrated Supply ModelThe biopharmaceutical sector is entering a new phase shaped by the clinical and commercial momentumof nucleic acid th...